baber/WOPTO huggingface dataset:
Patent CA-2606204-C (CA)
Title: Cutting segment for cutting tool and cutting tools
Inventor: KIM SOO-KWANG
IPC: B23D61/02
Filed: 2006-04-19
Granted: 2011-10-25
Abstract: The invention provides a cutting segment for a cutting tool for cutting or drilling a brittle work piece such as stone, bricks, concrete and asphalt, and a cutting tool having the cutting segment. The cutting segment includes a cutting surface for cutting a work piece and a plurality of abrasive particle layers. The abrasive particle layers are disposed perpendicular to a cutting direction. Each of the abrasive layers has a plurality of abrasive particle rows in a width direction of the cutting segment. Each of the abrasive rows has a plurality of abrasive particles arranged in a line. Further, the abrasive layers have a plurality of blank sections therebetween. In the blanks sections, abrasive particles are absent or have a concentration of 70% or less with respect to those in the abrasive rows. In addition, the blank sections include relatively thick blank sections and relatively thin blank sections.
Patent CA-2608384-C (CA)
Inventor: LAUTENBACH HOLGER
IPC: C09B67/26
Filed: 2006-05-08
Granted: 2012-11-27
Abstract: The invention relates to an aqueous dye solution comprising a) 5 to 30% by weight of an anionic or cationic direct dye, b) 0.01 to 5% by weight of the compound of formula (1), in which M represents hydrogen, an alkali metal or alkaline earth metal, ammonium or ammonium, that is mono-, di-, tri- or tetra-substituted by C1-C4alkyl or C2-C4hydroxyalkyl or mixtures thereof, c) 0 to 10% by weight of an inorganic or an organic acid, d) 0 to 20% by weight of further additives and e) water to complete to 100%, with the proviso that direct dyes of the formula (2) in which K is a residue of a coupling component of the acetoacetanilide, pyridone, pyrazolone or pyrimidine series and M is as defined above, are excluded, a process for their preparation and the use thereof for dyeing paper.
Patent CA-2609438-C (CA)
Title: Double-chamber mixing device for viscous pharmaceutical substances
Inventor: BONNARD ERIC
IPC: B01F15/06
Filed: 2006-05-23
Granted: 2014-07-08
Abstract: The invention concerns a double-chamber device for mixing at least two viscous substances, comprising: cylindrical and coaxial first (1) and second (2) communicating vessels, each hermetically sealed at one end by a mobile piston (12, 22) and provided at its second end with a slightly conical bottom end (11, 21), the two vessels (1, 2) being arranged, preferably vertically, in mirror symmetry relative to a meridian plane perpendicular to their common axis; a central mixing element (5) connecting the two vessels (1, 2) at the two slightly conical bottom ends (11, 21); a high-pressure hydraulic device for automatically activating the pistons in a coordinated reciprocating movement.
Patent CA-2612165-C (CA)
Inventor: FREEMAN PAUL N
IPC: H04B10/564
Filed: 2006-06-30
Granted: 2015-05-19
Abstract: A transmissive active channel element is provided in each signal channel of a monolithic multi-channel TxPIC where each channel also includes a modulated source. The active channel element functions both as a power control element for both monitoring and regulating the output channel signal level of each signal channel and as a modulator for channel wavelength tagging or labeling to provide for wavelength locking the modulated sources. The power regulating function is also employed to control the channel signal power outputs of each channel to be uniform across the channel signal array. All of these functions are carried out by a feedback loop utilizing digital signal processing.
Patent CA-2618287-C (CA)
Title: Separator for fuel cell and production process for the same
Inventor: KANBA NOBORU
IPC: H01M8/02
Filed: 2006-08-07
Granted: 2011-11-22
Abstract: In order to provide a separator for a fuel cell which is improved in cell characteristics by controlling a wetting property of the separator for a fuel cell and a production process for the same, assumed is a constitution in which in a separator A for a fuel cell molded from at least from a carbon material, a hydrophilic functional group is formed and increased on a surface part of a flow passage surface 11 in the separator 10 by irradiation treatment of a YAG laser apparatus 20 and in which an uneven part having an average surface roughness Ra of less than 50 µm is formed.
Patent CA-2618435-C (CA)
Inventor: MADSEN EDWARD B
IPC: A61M16/04
Filed: 2006-06-02
Granted: 2013-12-31
Abstract: A multilumen tracheal tube (12) or catheter is disclosed. The tube (12) has a plurality of ingress (44) and egress (45) lumens, each having a suction (40) or discharge (41) port as appropriate. At least one rotatable collar (38) is provided. The collar (38) is capable of selecting various combinations of suction (40) and discharge (41) ports without increasing the likelihood of cross contaminating any others .
Patent CA-2618769-C (CA)
Inventor: GILBERT MICHEL
IPC: C12P19/26
Filed: 2006-08-11
Granted: 2014-03-04
Abstract: The invention relates to sialate-O-acetyltransferase (SOAT) polypeptides, nucleic acids that encode the polypeptides, and methods of using the polypeptides.
Patent CA-2621373-C (CA)
Inventor: PACHECO OGARI
IPC: A61K39/00
Filed: 2006-09-12
Granted: 2014-05-27
Abstract: The present invention relates to a product named "immunogenic complex", which comprises an adjuvant characterized by solid particles of highly nanostructured mesoporous silica, preferably, the silica SBA-15, and vaccinal antigens of distinct nature, encapsulated in this kind of adjuvant. The immunogenic complex of the present invention allows the presentation of the antigens to lymphocytes, in a safe, gradual and sustained way, which leads to a more efficient immunological memory, increases in the immunogenicity of the antigen and improves the production of antibodies. It ensures efficient immunological protection with lower amounts of antigens and/or less repetition of vaccinal doses. In addition, the characteristics of the immunogenic complex of the present invention promote effective immunity induction, homogeneous in "high and low responder" individuals.
Patent CA-2621528-C (CA)
Inventor: JONES ERIC
IPC: A61F2/02
Filed: 2008-02-12
Granted: 2015-12-15
Abstract: A prosthetic implant which has an attachment portion for insertion into or attachment to a patient's bone without bone cement and in which the outer surface of the attachment portion which is to be attached to said bone has a first layer made of synthetic resin material over which is secured a second layer made of a metallic material, a first and proximal portion of said second layer being porous or roughened to encourage bone ingrowth or ongrowth and a second and distal portion of said second layer being less porous, substantially non-porous or less roughened in relation to the first portion, or smooth.
Patent CA-2621577-C (CA)
Inventor: KIDRON MIRIAM
IPC: A61K31/22
Filed: 2006-08-31
Granted: 2013-12-24
Abstract: This invention provides compositions comprising a protein and an omega-3 fatty acid, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.
Patent CA-2632032-C (CA)
Inventor: DAVIES DONNA
IPC: A61K38/21
Filed: 2008-05-16
Granted: 2016-01-12
Abstract: Utilisation de linterféron bêta (IFN- .bêta.) et/ou IFN-.lambda. pour le traitement dune infection à rhinovirus (RV) chez les personnes âgées, en particulier les personnes âgées qui sont ou ont été des fumeurs à long terme, plus particulièrement ceux qui présentent un historique clinique dinfections à RV récurrentes, et qui peuvent avoir dautres affections médicales, comme des troubles cardiaques ou circulatoires, et qui sont susceptibles de souffrir de complications graves ou de mortalité élevée à la suite dune pauvre habilité innée à combattre une telle infection virale.
Patent CA-2634240-C (CA)
Title: Method for extraction of hydrocarbon fuels or contaminants using electrical energy and critical fluids
Inventor: CONSIDINE BRIAN C
IPC: C09K8/594
Filed: 2006-09-12
Granted: 2011-10-18
Abstract: The extraction of hydrocarbon fuel products such as kerogen oil and gas from a body of fixed fossil fuels such as oil shale is accomplished by applying a combination of electrical energy and critical fluids with reactants and/or catalysts down a borehole to initiate a reaction of reactants in the critical fluids with kerogen in the oil shale thereby raising the temperatures to cause kerogen oil and gas products to be extracted as a vapor, liquid or dissolved in the critical fluids. The hydrocarbon fuel products of kerogen oil or shale oil and hydrocarbon gas are removed to the ground surface by a product return line. An RF generator provides electromagnetic energy, and the critical fluids include a combination of carbon dioxide (CO2), with reactants of nitrous oxide (N2O) or oxygen (O2).
Patent CA-2638596-C (CA)
Title: Endless cable system and associated methods
Inventor: KRUYER JAN
IPC: B01D17/022
Filed: 2008-08-06
Granted: 2014-10-07
Abstract: A separation apparatus can include at least one endless cable. The cable can be wrapped around at least two revolvable cylindrical members a plurality of times. The wraps can form gaps between adjacent windings, which, along with the endless cable, can be used to facilitate separations processing. Additionally, the separation apparatus can optionally include a repositioning guide for each multiple wrap endless cable that can guide the endless cable in an endless route and prevent the cable from rolling off or falling off of the cylindrical members. Separation can be accomplished by oleophilic adherence to the cable, electrostatic adherence to the cable, and/or physical retention on the cable. This endless cable system can be particularly useful for separation of oil sand slurries, mass transfer operations, and physical separations.
Patent CA-2640118-C (CA)
Inventor: FOLIN RICHARD
IPC: E21B19/08
Filed: 2007-01-22
Granted: 2014-05-06
Abstract: The object of the invention is to provide a telescopic feeder which is easier to handle. A first beam is intended to be used in sliding cooperation with a second beam in a telescopic feeder for a rock drilling machine. The first beam comprises at least one guiding stud intended to be guided into a recess in the second beam as the second beam and the first beam are retracted to an end position. The guiding stud is used for locking the first beam in relation to the second beam in a fixed position as the telescopic feeder is fully retracted to an end position.
Patent CA-2640713-C (CA)
Title: Wireless router system and method
Inventor: LEWIS ALLAN D
IPC: H04L12/28
Filed: 2001-12-21
Granted: 2011-11-15
Abstract: A wireless router employing a technique to couple a plurality of host services or host systems and a plurality of wireless networks. A method to route data items between a plurality of mobile devices and a plurality of host systems through a common wireless router. A  point--to-point communication connection is preferably established between a first host system and a common wireless router, a mobile network message at a mobile device is generated, and the mobile network message is transmitted via a wireless network to the common wireless router, which in turn routes a data item component of the mobile network message to the appropriate host service.
Patent CA-2641170-C (CA)
Inventor: SEVRAIN LIONEL C
IPC: A61K35/33
Filed: 2007-02-05
Granted: 2016-04-12
Abstract: Methods and compositions for the biological repair of cartilage using a hybrid construct combining both an inert structure and living core are described. The inert structure is intended to act not only as a delivery system to feed and grow a living core component, but also as an inducer of cell differentiation. The inert structure comprises concentric internal and external and inflatable/expandable balloon-like bio-polymers. The living core comprises the cell-matrix construct comprised of HDFs, for example, seeded in a scaffold. The method comprises surgically removing a damaged cartilage from a patient and inserting the hybrid construct into the cavity generated after the foregoing surgical intervention. The balloons of the inert structure are successively inflated within the target area, such as a joint, for example. Also disclosed herein are methods for growing and differentiating human fibroblasts into chondrocyte-like cells via mechanical strain.
Patent CA-2643819-C (CA)
Title: Flavivirus pseudo-infectieux et ses utilisations
Inventor: FROLOV ILYA
IPC: A61K39/12
Filed: 2007-02-27
Granted: 2018-11-27
Abstract: La présente invention concerne un virus pseudo-infectieux défectueux de réplication qui appartient à la famille des Flaviviridae, auquel manque le gène de capside, lequel virus pseudo-infectieux défectueux de réplication se propage uniquement dans des cellules qui expriment la capside ou les protéines prM et d'enveloppe de capside du flavivirus. Elle concerne aussi la méthode pour produire de tels virus à grande échelle et pour utiliser lesdits virus pseudo-infectieux comme vaccins pour prévenir des maladies causées par des infections d'êtres humains ou d'animaux par des virus appartenant à cette famille.
Patent CA-2648015-C (CA)
Title: Generalized interconnection apparatus for delivering services based on real time performance requirements
Inventor: SHAW VENSON
IPC: H04L47/80
Filed: 2007-05-01
Granted: 2012-06-05
Abstract: A system for interconnecting network operators with each other based on class of service is provided, taking real-time performance requirements for each service into consideration, as a result, services can be sent or received in real-time, with greater guarantee of network resources, in one non-limiting embodiment, the delivery path for service traffic is based on the real-time performance requirement categories assigned to each service during a pre-processing step. Thus, services having the highest real-time performance demands can be delivered faster using greater network resources, whereas the services without any real-time performance requirements are processed/delivered using fewer network resources.
Patent CA-2648086-C (CA)
Inventor: RUPRECHT RUTH
IPC: A61K39/21
Filed: 2007-03-28
Granted: 2014-05-13
Abstract: The invention provides methods and compositions for raising an immune response in a subject by administering an HIV antigen. The HIV antigens include HIV clade C polynucleotides and polypeptides. The invention also provides for recombinant HIV viral particles and compositions.
Patent CA-2660978-C (CA)
Title: Methods and devices for circulating air
Inventor: TIPLER ANDREW
IPC: F24F11/76
Filed: 2007-08-20
Granted: 2015-07-07
Abstract: A gas chromatography system comprising a sample introduction device, an oven coupled to the sample introduction device and a detector coupled to the oven is disclosed. In certain examples, the oven may be configured to receive a chromatography column in a space in the oven. In some examples, the oven may be constructed and arranged to provide a substantially constant temperature to the space during an analysis stage of the gas chromatography system.
Patent CA-2661504-C (CA)
Inventor: SANKARANARAYANAN RAMASWAMY
IPC: B24D3/20
Filed: 2007-07-13
Granted: 2013-04-23
Abstract: An abrasive article includes an abrasive layer having an array of protrusions. The abrasive layer has a thickness not greater than about 500 mils. The abrasive article is free of a backing layer.
Patent CA-2664913-C (CA)
Inventor: OGAWA YOSHIHIKO
IPC: H04W16/10
Filed: 2007-10-02
Granted: 2015-12-15
Abstract: Provided is a sequence allocation method capable of reducing inter-cell interference of a reference signal when a ZC sequence is used as the reference signal in a mobile communication system. In the sequence allocation method divides R x M sequences specified by a ZC sequence number r(r = 1 to R) and a cyclic shift sequence number m (m = 1 to M) into a plurality of sequence groups X (X = 1 to R) in accordance with the transmission band width of the reference signal, so that the ZC sequence is allocated to each cell in each sequence group unit. When it is assumed that R = 9 and M = 6, the number of sequence is 54. Each of the sequence groups is formed by two sequences. Accordingly, the number of sequence groups is 27. The 27 types of sequence groups are allocated to each cell.
Patent CA-2666852-C (CA)
Inventor: XIE ZAIKU
IPC: C07C11/06
Filed: 2007-10-19
Granted: 2013-05-28
Abstract: A process for producing light olefins from methanol and/or dimethyl ether comprising the steps of: (a) introducing a feed comprising methanol and/or dimethyl ether into a fluidized-bed reactor from its bottom, and reacting the feed in a dense phase zone and a transition zone of the fluidized-bed reactor by contacting it with a catalyst, to form an effluent I  comprising unreacted feed, reaction products and entrained solid particulate catalyst; (b) introducing a terminating agent at upper portion of the transition zone and/or lower portion of a gas-solid separating zone of the fluidized-bed reactor into the effluent I, to give an effluent II, wherein the terminating agent is at least one selected from the group consisting of water, C2 to C5 alcohols, C2 to C10 ethers, hydrocarbons having 4 or more carbon atoms, and C6 to C12 aromatic hydrocarbons; and (c) passing the effluent II into the gas-solid separating zone in upper portion of the fluidized-bed reactor, where gas-solid separation is accomplished to give a gaseous product stream and solid catalyst, said gaseous product stream being led to an aftertreatment stage, and said solid catalyst being circulated to the dense phase zone in lower portion of the fluidized-bed reactor or, alternatively, being led to a regenerator after having been stripped in a stripper, is disclosed.
Patent CA-2667343-C (CA)
Title: Solution medicamenteuse a teneur reduite en oxygene dissous, procede de production de celle-ci et emballage contenant une telle solution
Inventor: SUMIYOSHI NOBUAKI
IPC: A61K9/08
Filed: 2007-10-25
Granted: 2015-10-20
Abstract: La présente invention concerne une solution médicamenteuse qui a une teneur réduite en oxygène dissous et qui, par conséquent, souffre d'une légère dégradation provoquée par l'oxydation et qui a une grande stabilité dans le temps. La présente invention se rapporte également à un procédé de production de cette solution médicamenteuse ainsi qu'à une unité contenant la solution médicamenteuse, dans laquelle la solution médicamenteuse peut être conservée tout en conservant une faible teneur en oxygène dissous et qui, par conséquent, souffre d'une légère dégradation provoquée par l'oxydation et qui a une grande stabilité dans le temps. Une solution médicamenteuse qui a une teneur réduite en oxygène dissous pour arriver au but de la présente invention, peut être obtenue en suivant les étapes consistant à : conserver une solution médicamenteuse dans un conteneur de solution médicamenteuse (15) réalisé à partir d'un matériau plastique, qui a une perméabilité à l'oxygène à 25 °C et une humidité relative (HR) de 60 % à une atmosphère de 200 cm3/m2 sur 24 h ou plus dans les 12 heures qui suivent la stérilisation à la vapeur ou la stérilisation à l'eau chaude et qui a une perméabilité à l'oxygène à 25 °C et une HR de 60 % à une atmosphère de 100 cm3/m2sur 24 h ou moins à un état stable de perméabilité à l'oxygène, tenir de façon étanche le conteneur, le soumettre ensuite à une stérilisation à la vapeur ou à une stérilisation à l'eau chaude, le stocker dans un environnement adapté avec des moyens de désoxydation et, lorsque la perméabilité à l'oxygène dudit matériau plastique arrive à l'état stable, réguler la concentration en oxygène dissous du la solution médicamenteuse à 2 ppm ou moins.
Patent CA-2677131-C (CA)
Inventor: AMIN MINESH
IPC: G06F9/46
Filed: 2008-02-06
Granted: 2014-10-14
Abstract: The present invention is directed to a parallel processing infrastructure, which enables the robust design of task scheduler(s) and communication primitive(s). This is achieved, in one embodiment of the present invention, by decomposing the general problem of exploiting parallelism into three parts. First, an infrastructure is provided to track resources. Second, a method is offered by which to expose the tracking of the aforementioned resources to task scheduler(s) and communication primitive(s). Third, a method is established by which task scheduler(s) in turn may enable and/or disable communication primitive(s). In this manner, an improved parallel processing infrastructure is provided.
Patent CA-2685126-C (CA)
Inventor: IKEDA KEN
IPC: C07D489/02
Filed: 2008-04-24
Granted: 2015-04-14
Abstract: An object of the present invention is to provide a drug with a high therapeutic or prophylactic effect on dyskinesia, without accompanying aggravation of symptoms of the primary disease, and with fewer side effects. Accordingly, the present invention provides a therapeutic or prophylactic agent for dyskinesia, comprising as an effective component a compound having a 4,5-epoxy morphinan skeleton, which compound is represented by the Formula (I) below, or a pharmaceutically acceptable acid addition salt thereof: (see formula I) [wherein the double line composed of a dashed line and a solid line represents a double bond or single bond, R1 is C4-C7 cycloalkylalkyl, R2 is C1-C5 straight or branched alkyl, and B is -CH=CH-.]
Patent CA-2685295-C (CA)
Inventor: BAUM JAMES
IPC: A01N63/50
Filed: 2008-04-25
Granted: 2017-03-21
Abstract: A novel Bacillus thuringiensis crystal protein exhibiting insect inhibitory activity is disclosed. Growth of Lygus insects is significantly inhibited by providing the novel crystal protein in Lygus insect diet. Polynucleotides encoding the crystal protein, transgenic plants and microorganisms that contain the polynucleotides, isolated peptides derived from the crystal protein, and antibodies directed against the crystal protein are also provided. Methods of using the crystal protein and polynucleotides encoding the crystal protein to control Hemipteran insects are also disclosed.
Patent CA-2689438-C (CA)
Inventor: SHIN JEE-HYUN
IPC: A61K31/519
Filed: 2008-06-03
Granted: 2012-06-05
Abstract: Disclosed herein is a therapeutic agent for chronic heart failure comprising, as an effective ingredient, 5- [2-propyloxy- 5- (l-methyl-2-pyrrolidinyleneamidosulfonyl) phenyl] - 1 -methyl - propyl-l,6-dihydro-7H-pyrazolo(4,3-d)pyrimidine-7-one. The compound inhibits phosphodiesterase-5 (PDE-5), which catalyzes the intracellular degradation of cyclic guanosine monophosphatase (cGMP), thereby mitigating several signs of chronic heart failure, that is, thereby preventing left ventricular dilatation, decreasing ventricular wall thinning, lowering elevated cardiac and circulating levels of atrial natriuretic peptide (ANP), and inhibiting ventricular fibrosis. Also, the compound has advantages in that it reaches the maximal plasma level in a short time, has an in vivo half-life longer than conventional PDE-5 inhibitors, allowing decreased administration frequency, and has fewer side effects, thus ensuring safety. Thus, the compound is useful as a therapeutic agent for chronic heart failure.
Patent CA-2698780-C (CA)
Inventor: FLATT PETER RAYMOND
IPC: A61K38/26
Filed: 2008-09-08
Granted: 2017-06-06
Abstract: The present invention relates to a peptide analogue of glucagon-like peptide-1 (7-36), which is useful to prophylactically prevent, improve, or reverse the diminished cognitive function associated with these types of disorders, by increasing (or sustaining) the LTP of synaptic transmission. Moreover, sustaining LTP may find utility in the prophylaxis of neurological disease by delaying the onset of impaired cognitive processes, and could serve as a treatment, not only for the diminished cognitive function caused by neurodegeneration, but also for the dysfunctional cognitive processes associated with trauma or age.